Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 2,725 shares of common stock at an average price of $35.75, according to a Form 4 filing with the SEC.

Summary

• Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported a transaction involving the sale of company stock.
• On May 7, 2025, Dambkowski sold 2,725 shares of common stock at a weighted average price of $35.75.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following the transaction, Dambkowski still beneficially owns 244,448 shares of Apogee Therapeutics.
• The price range for the shares sold was between $35.23 and $36.09.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock sale by an officer. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure. The sale is pre-planned.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Apogee Therapeutics, Dambkowski, Chief Medical Officer, Stock Sale, Form 4, SEC, Rule 10b5-1, APGE, Beneficial Ownership